EQT To Acquire QIAGEN In €10.8 Billion Take-Private With ADIA And CPP Investments

QIAGEN has entered into an agreement supporting an all-cash voluntary public takeover offer from EQT Private Equity that values the life sciences and molecular diagnostics company at approximately €10.8 billion in enterprise value, or about $12.1 billion at current exchange rates.

Under the transaction, Crown NL Bidco, a holding company indirectly controlled by the EQT XI fund, will offer QIAGEN shareholders €46.50 in cash for each outstanding share.

The bidder also includes indirect co-investments from Luxinva, a wholly owned subsidiary of the Abu Dhabi Investment Authority, and CPP Investment Board Europe, a wholly owned subsidiary of CPP Investments.

The €46.50-per-share offer represents a 40.3% premium to QIAGEN’s €33.15 XETRA closing price on July 8, 2026, the last trading day before market reports emerged regarding potential private equity takeover interest. It also represents a 46.9% premium to QIAGEN’s three-month volume-weighted average share price through that date.

QIAGEN’s Supervisory Board and Managing Board unanimously support the transaction following a strategic review that included consideration of the company’s standalone prospects and discussions with both strategic and financial parties.

QIAGEN believes private ownership could provide greater flexibility to make long-term investments in product innovation, research and development, and strategic growth initiatives.

Under the business combination agreement, EQT has made commitments regarding QIAGEN’s strategy, key brands, operating footprint, R&D activities, employee arrangements, financing, and corporate culture. QIAGEN is expected to continue operating under its existing name and brand following completion.

EQT manages approximately €354 billion in assets and has invested more than €30 billion across over 210 healthcare companies globally. Its current and former healthcare investments include SPT Labtech, Galderma, Parexel, Aldevron, Dako, and HemoCue.

The takeover is subject to a minimum acceptance threshold of 50% of QIAGEN’s outstanding share capital plus one share, shareholder actions related to post-closing measures, and customary merger control, foreign investment, and other regulatory approvals.

EQT has secured committed equity and debt financing sufficient to fund the transaction and associated costs, and the deal is not subject to a financing condition. Morgan Stanley, Jefferies, Deutsche Bank, SMBC, Crédit Agricole, and UniCredit are supporting the committed debt financing.

After completion of the planned post-closing measures, QIAGEN’s listings on the Frankfurt Stock Exchange and New York Stock Exchange are expected to terminate.

The transaction is currently expected to close in mid-2027. Until then, QIAGEN will continue to operate independently under its current management.

QIAGEN serves more than 500,000 customers globally across life sciences and molecular diagnostics and employed approximately 5,400 people across more than 35 locations as of September 30, 2026.

KEY QUOTES:

“This transaction offers shareholders compelling value while positioning QIAGEN for its next phase of development under private ownership. After considering QIAGEN’s stand-alone strategic prospects and the alternatives available through discussions with strategic and financial parties, we unanimously concluded that this is the best path forward for QIAGEN, its shareholders and other stakeholders.”

Stephen H. Rusckowski, Chairman Of The Supervisory Board Of QIAGEN

“Since joining QIAGEN, I have seen firsthand the quality of our people, technologies and customer relationships. I also see clear opportunities to build on those strengths and do more for customers. Under private ownership, we can move faster and have greater freedom to put resources behind the most attractive opportunities that align best with our long-term strategy. That can help us grow the business in line with our priorities and create more opportunities for our people to innovate, develop their careers and help shape the future of QIAGEN.”

Jonathan M. Pratt, Chief Executive Officer Of QIAGEN

“This agreement provides our shareholders with an attractive premium while giving QIAGEN a strong partner that shares our strategic priorities and vision for the future. With EQT’s support and resources, we will strengthen our ability to pursue new opportunities and expand our capabilities, building on the excellent foundation our teams have created.”

Roland Sackers, Chief Financial Officer Of QIAGEN

“QIAGEN is an outstanding global leader in the life science tools and diagnostics market. We have closely followed the Company for many years and long admired the long-standing reputation and positive impact of its products and services, enabling customers to advance cutting-edge science, improve patient outcomes and gain valuable insights from biological samples. QIAGEN’s management team and employees have built an exceptional company with a portfolio of highly attractive products and respected brands, strong market positions and considerable technical expertise. EQT brings deep sector experience, a global network and operational capabilities, and we are proud to partner with QIAGEN’s highly talented and capable employees to further invest in QIAGEN’s continued product innovation and growth.”

Matteo Thun-Hohenstein, Partner At EQT

“This is a landmark transaction for EQT and a powerful reflection of the deep sector understanding, investment experience and network of expertise we have built over the last three decades. QIAGEN sits at the heart of modern life sciences and diagnostics, and we are thrilled to partner with it. We are proud to be investing alongside ADIA and CPP Investments, whose long-term perspective and experience with large-scale transactions make them outstanding partners.”

Michael Bauer, Global Co-Head Of Healthcare At EQT